RS BioTherapeutics, Inc.
October 17, 2023
Franciscan B
Infectious Diseases
Company Description: RS BioTherapeutics (RSBT) is developing a pharmaceutical compound for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other diseases characterized by pulmonary inflammation. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory and non-intoxicating cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RSBT is currently engaged with NIH in a Research Collaboration Agreement (RCA) to evaluate RSBT-001 in the prevention and treatment of IPF.
State
MD
Country
United States
Website
http://www.rsbiotherapeutics.com
CEO/Top Company Official
Dean Hart
Lead Product in Development
RSBT-001: RSBT-001 is a first-in-class agent in preclinical development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory and non-intoxicating cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is currently focused on developing RSBT-001 for IPF and COPD with projected IND filing in mid 2025.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
1
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)